JP2012500805A - 免疫抑制のための６−置換２−（ベンズイミダゾリル）プリンおよびプリノン誘導体ならびに６−置換２−（イミダゾロ［４，５−ｃ］ピリジニル）プリンおよびプリノン誘導体 - Google Patents
免疫抑制のための６−置換２−（ベンズイミダゾリル）プリンおよびプリノン誘導体ならびに６−置換２−（イミダゾロ［４，５−ｃ］ピリジニル）プリンおよびプリノン誘導体 Download PDFInfo
- Publication number
- JP2012500805A JP2012500805A JP2011524034A JP2011524034A JP2012500805A JP 2012500805 A JP2012500805 A JP 2012500805A JP 2011524034 A JP2011524034 A JP 2011524034A JP 2011524034 A JP2011524034 A JP 2011524034A JP 2012500805 A JP2012500805 A JP 2012500805A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- mmol
- aryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 6-Substituted 2- (benzimidazolyl) purine Chemical class 0.000 title claims description 139
- UFZNZKGKBWOSJG-UHFFFAOYSA-N purin-2-one Chemical class O=C1N=CC2=NC=NC2=N1 UFZNZKGKBWOSJG-UHFFFAOYSA-N 0.000 title description 5
- 206010062016 Immunosuppression Diseases 0.000 title description 3
- 230000001506 immunosuppresive effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 97
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 70
- 125000000623 heterocyclic group Chemical group 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical group 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 150000002431 hydrogen Chemical group 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 125000003386 piperidinyl group Chemical group 0.000 claims description 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 150000003857 carboxamides Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003725 azepanyl group Chemical group 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- QYJXLKYOBNZROU-UHFFFAOYSA-N carboxysulfonylformic acid Chemical group OC(=O)S(=O)(=O)C(O)=O QYJXLKYOBNZROU-UHFFFAOYSA-N 0.000 claims description 6
- 125000005959 diazepanyl group Chemical group 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 4
- JAAJQSRLGAYGKZ-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2C(O)CCCC2=C1 JAAJQSRLGAYGKZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 3
- 125000000676 alkoxyimino group Chemical group 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical group OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 claims description 2
- 125000003551 oxepanyl group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 210000003630 histaminocyte Anatomy 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 7
- 208000027866 inflammatory disease Diseases 0.000 abstract description 6
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 150000003212 purines Chemical class 0.000 abstract description 4
- 206010052779 Transplant rejections Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 159
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 150
- 239000007787 solid Substances 0.000 description 123
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 121
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 114
- 239000011541 reaction mixture Substances 0.000 description 87
- 239000000203 mixture Substances 0.000 description 70
- 239000000047 product Substances 0.000 description 69
- 238000000034 method Methods 0.000 description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 63
- 239000002904 solvent Substances 0.000 description 62
- 238000006243 chemical reaction Methods 0.000 description 59
- 235000019439 ethyl acetate Nutrition 0.000 description 56
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 238000000746 purification Methods 0.000 description 37
- 238000004128 high performance liquid chromatography Methods 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- 101150069380 JAK3 gene Proteins 0.000 description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 27
- 238000003756 stirring Methods 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 26
- 229910002027 silica gel Inorganic materials 0.000 description 26
- 238000001035 drying Methods 0.000 description 25
- 238000012544 monitoring process Methods 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- 239000011734 sodium Substances 0.000 description 22
- 238000010828 elution Methods 0.000 description 21
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 21
- 238000001704 evaporation Methods 0.000 description 20
- 230000008020 evaporation Effects 0.000 description 20
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 238000002953 preparative HPLC Methods 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 0 *c(cc1)cc2*1nc[n]2-c(nc1*)nc(N2*)c1N(*)C2=O Chemical compound *c(cc1)cc2*1nc[n]2-c(nc1*)nc(N2*)c1N(*)C2=O 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 15
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 239000004677 Nylon Substances 0.000 description 13
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 13
- 229910000024 caesium carbonate Inorganic materials 0.000 description 13
- 229920001778 nylon Polymers 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 229910052786 argon Inorganic materials 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- YLKYOEVXPMJDQM-UHFFFAOYSA-N 6-chloropurin-2-one Chemical compound ClC1=NC(=O)N=C2N=CN=C12 YLKYOEVXPMJDQM-UHFFFAOYSA-N 0.000 description 9
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000012362 glacial acetic acid Substances 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000006880 cross-coupling reaction Methods 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 208000024908 graft versus host disease Diseases 0.000 description 7
- 229940098779 methanesulfonic acid Drugs 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- HTFQCXHHEIUZPM-UHFFFAOYSA-N 3-(2-fluorophenoxy)propanoic acid Chemical compound OC(=O)CCOC1=CC=CC=C1F HTFQCXHHEIUZPM-UHFFFAOYSA-N 0.000 description 6
- HXACNHXAKSMYNU-UHFFFAOYSA-N 8-fluoro-3,4-dihydro-2h-chromen-4-amine Chemical compound C1=CC=C2C(N)CCOC2=C1F HXACNHXAKSMYNU-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000012746 preparative thin layer chromatography Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 5
- FKDMFDMYQZIZMI-UHFFFAOYSA-N 8-fluoro-2,3-dihydrochromen-4-one Chemical compound O=C1CCOC2=C1C=CC=C2F FKDMFDMYQZIZMI-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 150000001543 aryl boronic acids Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 229960003444 immunosuppressant agent Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LILACARBFWKAIR-UHFFFAOYSA-N 2-amino-6-chloro-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=NC(N)=NC(Cl)=C2NC(=O)N1C1CCOCC1 LILACARBFWKAIR-UHFFFAOYSA-N 0.000 description 4
- VGYVBEJDXIPSDL-UHFFFAOYSA-N 2-bromo-4-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1Br VGYVBEJDXIPSDL-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011097 chromatography purification Methods 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- CSNFMBGHUOSBFU-UHFFFAOYSA-N pyrimidine-2,4,5-triamine Chemical compound NC1=NC=C(N)C(N)=N1 CSNFMBGHUOSBFU-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- DYKTWSCZBLROFI-UHFFFAOYSA-N 2-amino-6-chloro-9-(4-hydroxycyclohexyl)-7h-purin-8-one Chemical compound C12=NC(N)=NC(Cl)=C2NC(=O)N1C1CCC(O)CC1 DYKTWSCZBLROFI-UHFFFAOYSA-N 0.000 description 3
- OMWDTYVGVCRRLN-UHFFFAOYSA-N 2-amino-9-(oxan-4-yl)-6-pyridin-4-yl-7h-purin-8-one Chemical compound C=12NC(=O)N(C3CCOCC3)C2=NC(N)=NC=1C1=CC=NC=C1 OMWDTYVGVCRRLN-UHFFFAOYSA-N 0.000 description 3
- VFMAPIFSXMBTQP-UHFFFAOYSA-N 2-bromo-4-chloro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1Br VFMAPIFSXMBTQP-UHFFFAOYSA-N 0.000 description 3
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 3
- QUHVRXKSQHIZNV-UHFFFAOYSA-N 3,3-difluoroazetidine Chemical compound FC1(F)CNC1 QUHVRXKSQHIZNV-UHFFFAOYSA-N 0.000 description 3
- RNDBDEZITHKFEU-UHFFFAOYSA-N 3-bromo-4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C=C1Br RNDBDEZITHKFEU-UHFFFAOYSA-N 0.000 description 3
- KDNBUJTVZJYLHI-UHFFFAOYSA-N 6-chloro-2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C12)=NC(Cl)=C1NC(=O)N2C1CCOCC1 KDNBUJTVZJYLHI-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001351 alkyl iodides Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- BEXWAXYTSUVJOB-SNVBAGLBSA-N n-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-2-methoxyacetamide Chemical compound C1=CC=C2[C@H](NC(=O)COC)CCOC2=C1F BEXWAXYTSUVJOB-SNVBAGLBSA-N 0.000 description 3
- 125000006501 nitrophenyl group Chemical group 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- HXACNHXAKSMYNU-QMMMGPOBSA-N (4s)-8-fluoro-3,4-dihydro-2h-chromen-4-amine Chemical compound C1=CC=C2[C@@H](N)CCOC2=C1F HXACNHXAKSMYNU-QMMMGPOBSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 2
- KVVCDQYSKUTBKQ-UHFFFAOYSA-N 2-(2-amino-5-chloroanilino)-6-chloro-9-(oxan-4-yl)-7h-purin-8-one Chemical compound NC1=CC=C(Cl)C=C1NC1=NC(Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 KVVCDQYSKUTBKQ-UHFFFAOYSA-N 0.000 description 2
- ZEHTZXMRRLJMTC-UHFFFAOYSA-N 2-(2-amino-5-chloroanilino)-9-(oxan-4-yl)-6-pyridin-4-yl-7h-purin-8-one Chemical compound NC1=CC=C(Cl)C=C1NC1=NC(C=2C=CN=CC=2)=C(NC(=O)N2C3CCOCC3)C2=N1 ZEHTZXMRRLJMTC-UHFFFAOYSA-N 0.000 description 2
- VINAKIWCTBTQDJ-UHFFFAOYSA-N 2-(2-amino-5-fluoroanilino)-6-(2-chlorophenyl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound NC1=CC=C(F)C=C1NC1=NC(C=2C(=CC=CC=2)Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 VINAKIWCTBTQDJ-UHFFFAOYSA-N 0.000 description 2
- KHIOKOBYCPLYBJ-UHFFFAOYSA-N 2-(2-amino-5-fluoroanilino)-6-chloro-9-(oxan-4-yl)-7h-purin-8-one Chemical compound NC1=CC=C(F)C=C1NC1=NC(Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 KHIOKOBYCPLYBJ-UHFFFAOYSA-N 0.000 description 2
- COXFBLUGJPLIEU-UHFFFAOYSA-N 2-(5-chloro-2-nitroanilino)-9-(oxan-4-yl)-6-pyridin-4-yl-7h-purin-8-one Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1NC1=NC(C=2C=CN=CC=2)=C(NC(=O)N2C3CCOCC3)C2=N1 COXFBLUGJPLIEU-UHFFFAOYSA-N 0.000 description 2
- KDIZLOZBCRTEOJ-LJQANCHMSA-N 2-(benzimidazol-1-yl)-4-n-[(4r)-6-fluoro-3,4-dihydro-2h-chromen-4-yl]-6-phenylpyrimidine-4,5-diamine Chemical compound NC1=C(N[C@H]2C3=CC(F)=CC=C3OCC2)N=C(N2C3=CC=CC=C3N=C2)N=C1C1=CC=CC=C1 KDIZLOZBCRTEOJ-LJQANCHMSA-N 0.000 description 2
- FAPKTYYVUSMMIC-UHFFFAOYSA-N 2-(benzimidazol-1-yl)-5-nitro-n-(oxan-4-yl)-6-phenylpyrimidin-4-amine Chemical compound N1=C(N2C3=CC=CC=C3N=C2)N=C(C=2C=CC=CC=2)C([N+](=O)[O-])=C1NC1CCOCC1 FAPKTYYVUSMMIC-UHFFFAOYSA-N 0.000 description 2
- GGHQYUNKXPSLJV-UHFFFAOYSA-N 2-amino-6-(2-chlorophenyl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C=12NC(=O)N(C3CCOCC3)C2=NC(N)=NC=1C1=CC=CC=C1Cl GGHQYUNKXPSLJV-UHFFFAOYSA-N 0.000 description 2
- BACXFRHGEVIZPV-UHFFFAOYSA-N 2-amino-6-chloro-7,9-dihydropurin-8-one Chemical compound NC1=NC(Cl)=C2NC(=O)NC2=N1 BACXFRHGEVIZPV-UHFFFAOYSA-N 0.000 description 2
- BJWWKRPYBNTTBC-MRVPVSSYSA-N 2-amino-6-chloro-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-7h-purin-8-one Chemical compound C1COC2=C(F)C=CC=C2[C@@H]1N1C(=O)NC2=C(Cl)N=C(N)N=C21 BJWWKRPYBNTTBC-MRVPVSSYSA-N 0.000 description 2
- JFYFFSJMUQSMPC-UHFFFAOYSA-N 2-benzylsulfanyl-6-(2-chlorophenyl)-5-nitro-n-(oxan-4-yl)pyrimidin-4-amine Chemical compound N1=C(SCC=2C=CC=CC=2)N=C(C=2C(=CC=CC=2)Cl)C([N+](=O)[O-])=C1NC1CCOCC1 JFYFFSJMUQSMPC-UHFFFAOYSA-N 0.000 description 2
- HCYSMGYMAYCENH-UHFFFAOYSA-N 2-benzylsulfanyl-6-chloro-5-nitro-n-(oxan-4-yl)pyrimidin-4-amine Chemical compound N1=C(NC2CCOCC2)C([N+](=O)[O-])=C(Cl)N=C1SCC1=CC=CC=C1 HCYSMGYMAYCENH-UHFFFAOYSA-N 0.000 description 2
- LMEWOXRLKHANRA-UHFFFAOYSA-N 2-benzylsulfonyl-6-(2-chlorophenyl)-5-nitro-n-(oxan-4-yl)pyrimidin-4-amine Chemical compound N1=C(S(=O)(=O)CC=2C=CC=CC=2)N=C(C=2C(=CC=CC=2)Cl)C([N+](=O)[O-])=C1NC1CCOCC1 LMEWOXRLKHANRA-UHFFFAOYSA-N 0.000 description 2
- LCPGLDQHVPTGOR-UHFFFAOYSA-N 2-chloro-5-nitro-n-(oxan-4-yl)-6-phenylpyrimidin-4-amine Chemical compound N1=C(Cl)N=C(C=2C=CC=CC=2)C([N+](=O)[O-])=C1NC1CCOCC1 LCPGLDQHVPTGOR-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 2
- BXQOQVXIENSALP-UHFFFAOYSA-N 3-(6-chloro-8-oxo-7,9-dihydropurin-2-yl)benzimidazole-5-carbonitrile Chemical compound C1=NC2=CC=C(C#N)C=C2N1C(N=C1Cl)=NC2=C1NC(=O)N2 BXQOQVXIENSALP-UHFFFAOYSA-N 0.000 description 2
- ONNXZQOHEYQASN-UHFFFAOYSA-N 3-[6-(3,3-difluoroazetidin-1-yl)-9-(4-hydroxycyclohexyl)-8-oxo-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound C1CC(O)CCC1N1C(=O)NC2=C(N3CC(F)(F)C3)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C21 ONNXZQOHEYQASN-UHFFFAOYSA-N 0.000 description 2
- XCWFLSBLGYEDKK-UHFFFAOYSA-N 3-[[6-chloro-9-(oxan-4-yl)-8-oxo-7h-purin-2-yl]amino]-4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C=C1NC1=NC(Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 XCWFLSBLGYEDKK-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- NICYTXJGZRYCEQ-UHFFFAOYSA-N 3h-benzimidazole-5-carbonitrile Chemical compound N#CC1=CC=C2N=CNC2=C1 NICYTXJGZRYCEQ-UHFFFAOYSA-N 0.000 description 2
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 2
- BBIJXSGGWSAYRZ-UHFFFAOYSA-N 4-[(2,5-diamino-6-chloropyrimidin-4-yl)amino]cyclohexan-1-ol Chemical compound NC1=NC(Cl)=C(N)C(NC2CCC(O)CC2)=N1 BBIJXSGGWSAYRZ-UHFFFAOYSA-N 0.000 description 2
- QLOVKSOHEHUBOQ-UHFFFAOYSA-N 4-[2-amino-9-(oxan-4-yl)-8-oxo-7h-purin-6-yl]benzonitrile Chemical compound C=12NC(=O)N(C3CCOCC3)C2=NC(N)=NC=1C1=CC=C(C#N)C=C1 QLOVKSOHEHUBOQ-UHFFFAOYSA-N 0.000 description 2
- BRPZONGSCLMVRY-UHFFFAOYSA-N 4-[2-benzylsulfanyl-5-nitro-6-(oxan-4-ylamino)pyrimidin-4-yl]benzonitrile Chemical compound N1=C(SCC=2C=CC=CC=2)N=C(C=2C=CC(=CC=2)C#N)C([N+](=O)[O-])=C1NC1CCOCC1 BRPZONGSCLMVRY-UHFFFAOYSA-N 0.000 description 2
- CUGFPIMZGLVAMJ-UHFFFAOYSA-N 4-[2-benzylsulfonyl-5-nitro-6-(oxan-4-ylamino)pyrimidin-4-yl]benzonitrile Chemical compound N1=C(S(=O)(=O)CC=2C=CC=CC=2)N=C(C=2C=CC(=CC=2)C#N)C([N+](=O)[O-])=C1NC1CCOCC1 CUGFPIMZGLVAMJ-UHFFFAOYSA-N 0.000 description 2
- VXCUSPQAKBNJCT-UHFFFAOYSA-N 4-amino-3-[[6-chloro-9-(oxan-4-yl)-8-oxo-7h-purin-2-yl]amino]benzonitrile Chemical compound NC1=CC=C(C#N)C=C1NC1=NC(Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 VXCUSPQAKBNJCT-UHFFFAOYSA-N 0.000 description 2
- CWNUZKROBZOONP-UHFFFAOYSA-N 6-(2-chlorophenyl)-2-(5-fluoro-2-nitroanilino)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1NC1=NC(C=2C(=CC=CC=2)Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 CWNUZKROBZOONP-UHFFFAOYSA-N 0.000 description 2
- ZVPBYCYSTLWCGC-UHFFFAOYSA-N 6-chloro-2-(5-fluoro-2-nitroanilino)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1NC1=NC(Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 ZVPBYCYSTLWCGC-UHFFFAOYSA-N 0.000 description 2
- MVILGOJJYHZDQI-CQSZACIVSA-N 6-chloro-2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-7h-purin-8-one Chemical compound C1COC2=C(F)C=CC=C2[C@@H]1N(C1=N2)C(=O)NC1=C(Cl)N=C2N1C=NC2=CC=C(F)C=C21 MVILGOJJYHZDQI-CQSZACIVSA-N 0.000 description 2
- ZVXRYABVTWAFCX-UHFFFAOYSA-N 6-chloro-4-n-(oxan-4-yl)pyrimidine-2,4,5-triamine Chemical compound NC1=NC(Cl)=C(N)C(NC2CCOCC2)=N1 ZVXRYABVTWAFCX-UHFFFAOYSA-N 0.000 description 2
- POUWVUXRFUTDBL-UHFFFAOYSA-N 6-chloro-8-methyl-9-(oxan-4-yl)purin-2-amine Chemical compound CC1=NC2=C(Cl)N=C(N)N=C2N1C1CCOCC1 POUWVUXRFUTDBL-UHFFFAOYSA-N 0.000 description 2
- SOMJHNVYNAJBGG-UHFFFAOYSA-N 6-chloropyrimidine-2,4,5-triamine;hydrochloride Chemical compound Cl.NC1=NC(N)=C(N)C(Cl)=N1 SOMJHNVYNAJBGG-UHFFFAOYSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- YPDSIEMYVQERLJ-UHFFFAOYSA-N 8-Hydroxypurine Chemical compound C1=NC=C2NC(O)=NC2=N1 YPDSIEMYVQERLJ-UHFFFAOYSA-N 0.000 description 2
- KPDRVLMDRATSLX-UHFFFAOYSA-N 8-methyl-9-(oxan-4-yl)-6-pyridin-4-ylpurin-2-amine Chemical compound CC1=NC2=C(C=3C=CN=CC=3)N=C(N)N=C2N1C1CCOCC1 KPDRVLMDRATSLX-UHFFFAOYSA-N 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- WSLGPUSLBNYPAE-JOCQHMNTSA-N C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C21 Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C21 WSLGPUSLBNYPAE-JOCQHMNTSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 101150009057 JAK2 gene Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- LQWJDVVMLCBJAN-UHFFFAOYSA-N [4-(2-amino-6-chloro-8-oxo-7h-purin-9-yl)cyclohexyl] methyl carbonate Chemical compound C1CC(OC(=O)OC)CCC1N1C(=O)NC2=C(Cl)N=C(N)N=C21 LQWJDVVMLCBJAN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- HAZJXELXJAWKQA-UHFFFAOYSA-N n-(5-chloro-2-nitrophenyl)-8-methyl-9-(oxan-4-yl)-6-pyridin-4-ylpurin-2-amine Chemical compound N1=C2N(C3CCOCC3)C(C)=NC2=C(C=2C=CN=CC=2)N=C1NC1=CC(Cl)=CC=C1[N+]([O-])=O HAZJXELXJAWKQA-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- PYNGJNRUPBSSJG-NXEZZACHSA-N (1r,4r)-4-amino-1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2[C@H](N)CC[C@@H](O)C2=C1 PYNGJNRUPBSSJG-NXEZZACHSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 1
- LENYOXXELREKGZ-WCCKRBBISA-N (3s)-3-fluoropyrrolidin-1-ium;chloride Chemical compound Cl.F[C@H]1CCNC1 LENYOXXELREKGZ-WCCKRBBISA-N 0.000 description 1
- WVQYSVLMDHXHOV-MRVPVSSYSA-N (4r)-6-fluoro-3,4-dihydro-2h-chromen-4-amine Chemical compound C1=C(F)C=C2[C@H](N)CCOC2=C1 WVQYSVLMDHXHOV-MRVPVSSYSA-N 0.000 description 1
- CDKWCMPLLLFKBM-DDWIOCJRSA-N (4r)-8-fluoro-3,4-dihydro-2h-chromen-4-amine;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](N)CCOC2=C1F CDKWCMPLLLFKBM-DDWIOCJRSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QMDUEBURHKSKDG-UHFFFAOYSA-N 1-pyridin-3-ylethanol Chemical compound CC(O)C1=CC=CN=C1 QMDUEBURHKSKDG-UHFFFAOYSA-N 0.000 description 1
- KEZNMOUMHOZFRA-UHFFFAOYSA-N 1h-pyrazol-4-ylboronic acid Chemical compound OB(O)C=1C=NNC=1 KEZNMOUMHOZFRA-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VUQYBVYYRREKMC-UHFFFAOYSA-N 2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1.C1=CC=C2C(=O)CCC2=C1 VUQYBVYYRREKMC-UHFFFAOYSA-N 0.000 description 1
- KDMMRYSLGGCOHT-UHFFFAOYSA-N 2,4-dichloro-5-nitro-6-phenylpyrimidine Chemical compound [O-][N+](=O)C1=C(Cl)N=C(Cl)N=C1C1=CC=CC=C1 KDMMRYSLGGCOHT-UHFFFAOYSA-N 0.000 description 1
- RVZMPNMUBCAPQO-UHFFFAOYSA-N 2,4-dimethoxyquinazoline Chemical class C1=CC=CC2=NC(OC)=NC(OC)=C21 RVZMPNMUBCAPQO-UHFFFAOYSA-N 0.000 description 1
- DWNSEFDMOYDZGO-CQSZACIVSA-N 2-(2-amino-5-fluoroanilino)-6-chloro-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-7h-purin-8-one Chemical compound NC1=CC=C(F)C=C1NC1=NC(Cl)=C(NC(=O)N2[C@H]3C4=CC=CC(F)=C4OCC3)C2=N1 DWNSEFDMOYDZGO-CQSZACIVSA-N 0.000 description 1
- CBVSHFAFTKAWAR-UHFFFAOYSA-N 2-(6-chlorobenzimidazol-1-yl)-6-(3,3-difluoroazetidin-1-yl)-7-methyl-9-(oxan-4-yl)purin-8-one Chemical compound O=C1N(C)C2=C(N3CC(F)(F)C3)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C2N1C1CCOCC1 CBVSHFAFTKAWAR-UHFFFAOYSA-N 0.000 description 1
- HMJIDQAHBRTOFU-UHFFFAOYSA-N 2-(6-chlorobenzimidazol-1-yl)-6-(3,3-difluoroazetidin-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C1C(F)(F)CN1C1=NC(N2C3=CC(Cl)=CC=C3N=C2)=NC2=C1NC(=O)N2C1CCOCC1 HMJIDQAHBRTOFU-UHFFFAOYSA-N 0.000 description 1
- LSGKAYOZMAGGDM-UHFFFAOYSA-N 2-(6-chlorobenzimidazol-1-yl)-6-(3-hydroxyazetidin-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C1C(O)CN1C1=NC(N2C3=CC(Cl)=CC=C3N=C2)=NC2=C1NC(=O)N2C1CCOCC1 LSGKAYOZMAGGDM-UHFFFAOYSA-N 0.000 description 1
- CRCMPBQKDVDVHP-UHFFFAOYSA-N 2-(6-chlorobenzimidazol-1-yl)-8-methyl-9-(oxan-4-yl)-6-pyridin-4-ylpurine Chemical compound CC1=NC2=C(C=3C=CN=CC=3)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C2N1C1CCOCC1 CRCMPBQKDVDVHP-UHFFFAOYSA-N 0.000 description 1
- JTYMHUQWRDQZSO-UHFFFAOYSA-N 2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-6-(piperidine-1-carbonyl)-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1C(=O)N1CCCCC1 JTYMHUQWRDQZSO-UHFFFAOYSA-N 0.000 description 1
- KSPVCRJIQXMXLF-QGZVFWFLSA-N 2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-6-(3-hydroxyazetidin-1-yl)-7h-purin-8-one Chemical compound C1C(O)CN1C1=NC(N2C3=CC(F)=CC=C3N=C2)=NC2=C1NC(=O)N2[C@H]1C2=CC=CC(F)=C2OCC1 KSPVCRJIQXMXLF-QGZVFWFLSA-N 0.000 description 1
- HQIMQRWFVQLYCW-HXUWFJFHSA-N 2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-6-phenyl-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N([C@H]2C3=CC=CC(F)=C3OCC2)C(=O)NC1=1)=NC=1C1=CC=CC=C1 HQIMQRWFVQLYCW-HXUWFJFHSA-N 0.000 description 1
- IEGOABAJYMWUSE-UHFFFAOYSA-N 2-(benzimidazol-1-yl)-9-(oxan-4-yl)-6-phenyl-7h-purin-8-one Chemical compound O=C1NC2=C(C=3C=CC=CC=3)N=C(N3C4=CC=CC=C4N=C3)N=C2N1C1CCOCC1 IEGOABAJYMWUSE-UHFFFAOYSA-N 0.000 description 1
- AEOQQLOLXFTBBF-LJQANCHMSA-N 2-(benzimidazol-1-yl)-n-[(4r)-6-fluoro-3,4-dihydro-2h-chromen-4-yl]-5-nitro-6-phenylpyrimidin-4-amine Chemical compound [O-][N+](=O)C1=C(N[C@H]2C3=CC(F)=CC=C3OCC2)N=C(N2C3=CC=CC=C3N=C2)N=C1C1=CC=CC=C1 AEOQQLOLXFTBBF-LJQANCHMSA-N 0.000 description 1
- CIBPYKZLYKJFGF-UHFFFAOYSA-N 2-(oxan-4-yl)-7,9-dihydropurin-8-one Chemical compound O1CCC(CC1)C1=NC=C2NC(NC2=N1)=O CIBPYKZLYKJFGF-UHFFFAOYSA-N 0.000 description 1
- HUFXKJVKRFXSCU-UHFFFAOYSA-N 2-(oxan-4-yl)pyrimidin-4-amine Chemical compound NC1=CC=NC(C2CCOCC2)=N1 HUFXKJVKRFXSCU-UHFFFAOYSA-N 0.000 description 1
- WSIREANZOIOZRV-UHFFFAOYSA-N 2-(oxan-4-yl)pyrimidine-4,5-diamine Chemical compound N1=C(N)C(N)=CN=C1C1CCOCC1 WSIREANZOIOZRV-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- QTXLQPDSLBHWPF-UHFFFAOYSA-N 2-[2-(2,5-dimethylpyrrol-1-yl)-5-(trifluoromethoxy)anilino]-9-(oxan-4-yl)-6-pyridin-4-yl-7h-purin-8-one Chemical compound CC1=CC=C(C)N1C1=CC=C(OC(F)(F)F)C=C1NC1=NC(C=2C=CN=CC=2)=C(NC(=O)N2C3CCOCC3)C2=N1 QTXLQPDSLBHWPF-UHFFFAOYSA-N 0.000 description 1
- ZYBBWVMFTRWSKM-UHFFFAOYSA-N 2-[2-amino-5-(trifluoromethoxy)anilino]-9-(oxan-4-yl)-6-pyridin-4-yl-7h-purin-8-one Chemical compound NC1=CC=C(OC(F)(F)F)C=C1NC1=NC(C=2C=CN=CC=2)=C(NC(=O)N2C3CCOCC3)C2=N1 ZYBBWVMFTRWSKM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MVAWATQAHDUZQJ-UHFFFAOYSA-N 2-amino-6-chloro-9-(4-methoxycyclohexyl)-7h-purin-8-one Chemical compound C1CC(OC)CCC1N1C(=O)NC2=C(Cl)N=C(N)N=C21 MVAWATQAHDUZQJ-UHFFFAOYSA-N 0.000 description 1
- FONJIJWCXJZLND-UHFFFAOYSA-N 2-benzylsulfanyl-4,6-dichloro-5-nitropyrimidine Chemical compound N1=C(Cl)C([N+](=O)[O-])=C(Cl)N=C1SCC1=CC=CC=C1 FONJIJWCXJZLND-UHFFFAOYSA-N 0.000 description 1
- CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
- KKQPWVOGOSKRPT-CQSZACIVSA-N 2-chloro-n-[(4r)-6-fluoro-3,4-dihydro-2h-chromen-4-yl]-5-nitro-6-phenylpyrimidin-4-amine Chemical compound [O-][N+](=O)C1=C(N[C@H]2C3=CC(F)=CC=C3OCC2)N=C(Cl)N=C1C1=CC=CC=C1 KKQPWVOGOSKRPT-CQSZACIVSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical group OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- SJSBKIXOCNOEFF-UHFFFAOYSA-N 2h-thiopyran 1,1-dioxide Chemical compound O=S1(=O)CC=CC=C1 SJSBKIXOCNOEFF-UHFFFAOYSA-N 0.000 description 1
- NXKQLUJKWVTJIM-UHFFFAOYSA-N 3-[(6-chloro-8-oxo-7,9-dihydropurin-2-yl)amino]-4-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(C#N)C=C1NC1=NC(Cl)=C(NC(=O)N2)C2=N1 NXKQLUJKWVTJIM-UHFFFAOYSA-N 0.000 description 1
- FXNWFHZWTZLZTJ-UHFFFAOYSA-N 3-[6-(3,3-difluoroazetidin-1-yl)-8-oxo-7,9-dihydropurin-2-yl]benzimidazole-5-carbonitrile Chemical compound C1C(F)(F)CN1C1=NC(N2C3=CC(=CC=C3N=C2)C#N)=NC2=C1NC(=O)N2 FXNWFHZWTZLZTJ-UHFFFAOYSA-N 0.000 description 1
- RMDMOYMMOIDUKC-UHFFFAOYSA-N 3-[6-(3,3-difluoroazetidin-1-yl)-8-oxo-9-(1-pyridin-3-ylethyl)-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound C12=NC(N3C4=CC(=CC=C4N=C3)C#N)=NC(N3CC(F)(F)C3)=C2NC(=O)N1C(C)C1=CC=CN=C1 RMDMOYMMOIDUKC-UHFFFAOYSA-N 0.000 description 1
- LWGSYYASBQTCAE-UHFFFAOYSA-N 3-[6-(3,3-difluoroazetidin-1-yl)-8-oxo-9-(oxolan-3-ylmethyl)-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound C1C(F)(F)CN1C1=NC(N2C3=CC(=CC=C3N=C2)C#N)=NC2=C1NC(=O)N2CC1COCC1 LWGSYYASBQTCAE-UHFFFAOYSA-N 0.000 description 1
- QTYRNLRKPMDQDZ-UHFFFAOYSA-N 3-[6-(3,3-difluoroazetidin-1-yl)-9-(oxan-4-yl)-8-oxo-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound C1C(F)(F)CN1C1=NC(N2C3=CC(=CC=C3N=C2)C#N)=NC2=C1NC(=O)N2C1CCOCC1 QTYRNLRKPMDQDZ-UHFFFAOYSA-N 0.000 description 1
- DSQUAEYHDOXNGW-TZIWHRDSSA-N 3-[6-(3-hydroxyazetidin-1-yl)-9-[(1r,4r)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl]-8-oxo-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound C1C(O)CN1C1=NC(N2C3=CC(=CC=C3N=C2)C#N)=NC2=C1NC(=O)N2[C@H]1C2=CC=CC=C2[C@H](O)CC1 DSQUAEYHDOXNGW-TZIWHRDSSA-N 0.000 description 1
- WTHBJEJJYSOYGH-UHFFFAOYSA-N 3-[6-(cyclopropylmethylamino)-9-(oxan-4-yl)-8-oxo-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound N1=C(N2C3=CC(=CC=C3N=C2)C#N)N=C2N(C3CCOCC3)C(=O)NC2=C1NCC1CC1 WTHBJEJJYSOYGH-UHFFFAOYSA-N 0.000 description 1
- DWMMKUNSPINXMH-UHFFFAOYSA-N 3-[6-chloro-8-oxo-9-(1-pyridin-3-ylethyl)-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound C12=NC(N3C4=CC(=CC=C4N=C3)C#N)=NC(Cl)=C2NC(=O)N1C(C)C1=CC=CN=C1 DWMMKUNSPINXMH-UHFFFAOYSA-N 0.000 description 1
- OCJJQVCBZZVWEY-UHFFFAOYSA-N 3-[6-chloro-9-(4-hydroxycyclohexyl)-7-methyl-8-oxopurin-2-yl]benzimidazole-5-carbonitrile Chemical compound O=C1N(C)C2=C(Cl)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C2N1C1CCC(O)CC1 OCJJQVCBZZVWEY-UHFFFAOYSA-N 0.000 description 1
- QEGZCZYZKZUVIW-UHFFFAOYSA-N 3-[6-chloro-9-(oxan-4-yl)-8-oxo-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound O=C1NC=2C(Cl)=NC(N3C4=CC(=CC=C4N=C3)C#N)=NC=2N1C1CCOCC1 QEGZCZYZKZUVIW-UHFFFAOYSA-N 0.000 description 1
- CHKNVGIKJHETJU-UHFFFAOYSA-N 3-[6-morpholin-4-yl-9-(oxan-4-yl)-8-oxo-7h-purin-2-yl]benzimidazole-5-carbonitrile Chemical compound O=C1NC2=C(N3CCOCC3)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C2N1C1CCOCC1 CHKNVGIKJHETJU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-N 3-bromopropanoic acid Chemical compound OC(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-N 0.000 description 1
- ZXWGHENZKVQKPX-UHFFFAOYSA-N 4,6-dichloropyrimidine-2,5-diamine Chemical compound NC1=NC(Cl)=C(N)C(Cl)=N1 ZXWGHENZKVQKPX-UHFFFAOYSA-N 0.000 description 1
- NLTIETZTDSJANS-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC=C1 NLTIETZTDSJANS-UHFFFAOYSA-N 0.000 description 1
- JQZSHFBWXMFIAQ-UHFFFAOYSA-N 4-(8-fluoro-3,4-dihydro-2H-chromen-4-yl)-1H-pyrimidine-2,4,5-triamine Chemical compound FC=1C=CC=C2C(CCOC12)C1(NC(=NC=C1N)N)N JQZSHFBWXMFIAQ-UHFFFAOYSA-N 0.000 description 1
- HUEGZISOONVGEM-UHFFFAOYSA-N 4-(oxan-4-yl)pyrimidine Chemical compound O1CCC(CC1)C1=NC=NC=C1 HUEGZISOONVGEM-UHFFFAOYSA-N 0.000 description 1
- HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 1
- BDHYIOWUKWTFLI-UHFFFAOYSA-N 4-[2-(2-amino-5-fluoroanilino)-9-(oxan-4-yl)-8-oxo-7h-purin-6-yl]benzonitrile Chemical compound NC1=CC=C(F)C=C1NC1=NC(C=2C=CC(=CC=2)C#N)=C(NC(=O)N2C3CCOCC3)C2=N1 BDHYIOWUKWTFLI-UHFFFAOYSA-N 0.000 description 1
- BEZRAIFOHWITHN-UHFFFAOYSA-N 4-[2-(5-fluoro-2-nitroanilino)-9-(oxan-4-yl)-8-oxo-7h-purin-6-yl]benzonitrile Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1NC1=NC(C=2C=CC(=CC=2)C#N)=C(NC(=O)N2C3CCOCC3)C2=N1 BEZRAIFOHWITHN-UHFFFAOYSA-N 0.000 description 1
- WWXOUDXOAKXFNZ-UHFFFAOYSA-N 4-[2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-8-oxo-7h-purin-6-yl]benzonitrile Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1C1=CC=C(C#N)C=C1 WWXOUDXOAKXFNZ-UHFFFAOYSA-N 0.000 description 1
- OYFZETUPONVUCZ-LJQANCHMSA-N 4-[2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-8-oxo-7h-purin-6-yl]butanenitrile Chemical compound C1COC2=C(F)C=CC=C2[C@@H]1N(C1=N2)C(=O)NC1=C(CCCC#N)N=C2N1C=NC2=CC=C(F)C=C21 OYFZETUPONVUCZ-LJQANCHMSA-N 0.000 description 1
- VRILBCMSATZYHI-UHFFFAOYSA-N 4-[2-amino-5-nitro-6-(oxan-4-ylamino)pyrimidin-4-yl]benzonitrile Chemical compound [O-][N+](=O)C=1C(C=2C=CC(=CC=2)C#N)=NC(N)=NC=1NC1CCOCC1 VRILBCMSATZYHI-UHFFFAOYSA-N 0.000 description 1
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 1
- YMUIVOGLHKEGEI-UHFFFAOYSA-N 4-chloro-2-n-[8-methyl-9-(oxan-4-yl)-6-pyridin-4-ylpurin-2-yl]benzene-1,2-diamine Chemical compound N1=C2N(C3CCOCC3)C(C)=NC2=C(C=2C=CN=CC=2)N=C1NC1=CC(Cl)=CC=C1N YMUIVOGLHKEGEI-UHFFFAOYSA-N 0.000 description 1
- SDMXLAZIFYYECU-UHFFFAOYSA-N 4-methoxycyclohexan-1-amine Chemical compound COC1CCC(N)CC1 SDMXLAZIFYYECU-UHFFFAOYSA-N 0.000 description 1
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 1
- VJCYOUSOQQATEE-UHFFFAOYSA-N 5-(oxan-4-yl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1C1CCOCC1 VJCYOUSOQQATEE-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- QQWYFAQNZRLRKU-UHFFFAOYSA-N 5-nitro-4-phenylpyrimidine Chemical compound [N+](=O)([O-])C=1C=NC=NC1C1=CC=CC=C1 QQWYFAQNZRLRKU-UHFFFAOYSA-N 0.000 description 1
- AZEOGOHFLAMNKX-UHFFFAOYSA-N 6-(2-chlorophenyl)-2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1C1=CC=CC=C1Cl AZEOGOHFLAMNKX-UHFFFAOYSA-N 0.000 description 1
- PIZPQWNUNHYKFC-UHFFFAOYSA-N 6-(2-chlorophenyl)-4-n-(oxan-4-yl)pyrimidine-2,4,5-triamine Chemical compound NC=1C(C=2C(=CC=CC=2)Cl)=NC(N)=NC=1NC1CCOCC1 PIZPQWNUNHYKFC-UHFFFAOYSA-N 0.000 description 1
- CZQIZAWWHSRXRJ-UHFFFAOYSA-N 6-(2-chlorophenyl)-5-nitro-4-n-(oxan-4-yl)pyrimidine-2,4-diamine Chemical compound [O-][N+](=O)C=1C(C=2C(=CC=CC=2)Cl)=NC(N)=NC=1NC1CCOCC1 CZQIZAWWHSRXRJ-UHFFFAOYSA-N 0.000 description 1
- SCZMVZXFLXISSU-UHFFFAOYSA-N 6-(4,4-difluoropiperidin-1-yl)-2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1N1CCC(F)(F)CC1 SCZMVZXFLXISSU-UHFFFAOYSA-N 0.000 description 1
- ASOWCSJFDIKYOY-QGZVFWFLSA-N 6-(azetidin-1-yl)-2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N([C@H]2C3=CC=CC(F)=C3OCC2)C(=O)NC1=1)=NC=1N1CCC1 ASOWCSJFDIKYOY-QGZVFWFLSA-N 0.000 description 1
- RAUBPHGIFOSJSY-UHFFFAOYSA-N 6-(cyclobutylamino)-2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1NC1CCC1 RAUBPHGIFOSJSY-UHFFFAOYSA-N 0.000 description 1
- AAZKTHBREUYIDZ-GOSISDBHSA-N 6-(cyclopropylmethylamino)-2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N([C@H]2C3=CC=CC(F)=C3OCC2)C(=O)NC1=1)=NC=1NCC1CC1 AAZKTHBREUYIDZ-GOSISDBHSA-N 0.000 description 1
- RWZPTGGXZYWNHC-JOCHJYFZSA-N 6-benzyl-2-(6-fluorobenzimidazol-1-yl)-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N([C@H]2C3=CC=CC(F)=C3OCC2)C(=O)NC1=1)=NC=1CC1=CC=CC=C1 RWZPTGGXZYWNHC-JOCHJYFZSA-N 0.000 description 1
- RIRHXBALKPGCJE-UHFFFAOYSA-N 6-chloro-2-(5-chloro-2-nitroanilino)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1NC1=NC(Cl)=C(NC(=O)N2C3CCOCC3)C2=N1 RIRHXBALKPGCJE-UHFFFAOYSA-N 0.000 description 1
- DWHXDBJIQQVCNL-UHFFFAOYSA-N 6-chloro-2-(6-chlorobenzimidazol-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=CC(Cl)=CC=C2N=CN1C(N=C12)=NC(Cl)=C1NC(=O)N2C1CCOCC1 DWHXDBJIQQVCNL-UHFFFAOYSA-N 0.000 description 1
- PLFDNFHPGQPJFU-UHFFFAOYSA-N 6-chloro-2-(6-fluorobenzimidazol-1-yl)-9-(4-hydroxycyclohexyl)-7-methylpurin-8-one Chemical compound O=C1N(C)C2=C(Cl)N=C(N3C4=CC(F)=CC=C4N=C3)N=C2N1C1CCC(O)CC1 PLFDNFHPGQPJFU-UHFFFAOYSA-N 0.000 description 1
- SCDFLZNZDNUZRY-UHFFFAOYSA-N 6-chloro-2-(6-fluorobenzimidazol-1-yl)-9-[4-(oxan-2-yloxy)cyclohexyl]-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C12)=NC(Cl)=C1NC(=O)N2C(CC1)CCC1OC1CCCCO1 SCDFLZNZDNUZRY-UHFFFAOYSA-N 0.000 description 1
- BLOJJKRFEQXTFS-CYBMUJFWSA-N 6-chloro-9-[(4r)-8-fluoro-3,4-dihydro-2h-chromen-4-yl]-2-(5-fluoro-2-nitroanilino)-7h-purin-8-one Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1NC1=NC(Cl)=C(NC(=O)N2[C@H]3C4=CC=CC(F)=C4OCC3)C2=N1 BLOJJKRFEQXTFS-CYBMUJFWSA-N 0.000 description 1
- MSQSVBUOUQQZEE-UHFFFAOYSA-N 6-cyclobutyl-2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1C1CCC1 MSQSVBUOUQQZEE-UHFFFAOYSA-N 0.000 description 1
- AFVGCPMOKAGRMG-UHFFFAOYSA-N 6-cyclobutyloxy-2-(6-fluorobenzimidazol-1-yl)-9-(oxan-4-yl)-7h-purin-8-one Chemical compound C12=CC(F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1OC1CCC1 AFVGCPMOKAGRMG-UHFFFAOYSA-N 0.000 description 1
- ZZERPPZUMBLBLA-UHFFFAOYSA-N 9-(oxan-4-yl)-6-pyridin-4-yl-2-[6-(trifluoromethoxy)benzimidazol-1-yl]-7h-purin-8-one Chemical compound C12=CC(OC(F)(F)F)=CC=C2N=CN1C(N=C1N(C2CCOCC2)C(=O)NC1=1)=NC=1C1=CC=NC=C1 ZZERPPZUMBLBLA-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DYKTWSCZBLROFI-IZLXSQMJSA-N C12=NC(N)=NC(Cl)=C2NC(=O)N1[C@H]1CC[C@H](O)CC1 Chemical compound C12=NC(N)=NC(Cl)=C2NC(=O)N1[C@H]1CC[C@H](O)CC1 DYKTWSCZBLROFI-IZLXSQMJSA-N 0.000 description 1
- JWSNTMMGKSDPHH-XYPYZODXSA-N C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(N3C4=CC(F)=CC=C4N=C3)N=C21 Chemical compound C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(N3C4=CC(F)=CC=C4N=C3)N=C21 JWSNTMMGKSDPHH-XYPYZODXSA-N 0.000 description 1
- GAUKCWIITXNWPT-MGCOHNPYSA-N C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(NC=3C(=CC=C(F)C=3)[N+]([O-])=O)N=C21 Chemical compound C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(NC=3C(=CC=C(F)C=3)[N+]([O-])=O)N=C21 GAUKCWIITXNWPT-MGCOHNPYSA-N 0.000 description 1
- PDLAEKXROHFZPV-JOCQHMNTSA-N C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(N3CC(F)(F)C3)N=C(N3C4=CC(F)=CC=C4N=C3)N=C21 Chemical compound C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(N3CC(F)(F)C3)N=C(N3C4=CC(F)=CC=C4N=C3)N=C21 PDLAEKXROHFZPV-JOCQHMNTSA-N 0.000 description 1
- OFTQSRVOYCTIPL-XYPYZODXSA-N C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(O)N=C(N3C4=CC(F)=CC=C4N=C3)N=C21 Chemical compound C1C[C@@H](O)CC[C@@H]1N1C(=O)NC2=C(O)N=C(N3C4=CC(F)=CC=C4N=C3)N=C21 OFTQSRVOYCTIPL-XYPYZODXSA-N 0.000 description 1
- ATVWJHZJQCNAOQ-HDJSIYSDSA-N C1C[C@@H](OC)CC[C@@H]1N1C(=O)N(C)C2=C(Cl)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C21 Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C(=O)N(C)C2=C(Cl)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C21 ATVWJHZJQCNAOQ-HDJSIYSDSA-N 0.000 description 1
- JMPHUUFXBNJIKA-JOCQHMNTSA-N C1C[C@@H](OC)CC[C@@H]1N1C(=O)N(C)C2=C(Cl)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C21 Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C(=O)N(C)C2=C(Cl)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C21 JMPHUUFXBNJIKA-JOCQHMNTSA-N 0.000 description 1
- MVAWATQAHDUZQJ-LJGSYFOKSA-N C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(N)N=C21 Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(N)N=C21 MVAWATQAHDUZQJ-LJGSYFOKSA-N 0.000 description 1
- CDQXMDLULZIOII-HAQNSBGRSA-N C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(NC=3C(=CC=C(C=3)C#N)[N+]([O-])=O)N=C21 Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(NC=3C(=CC=C(C=3)C#N)[N+]([O-])=O)N=C21 CDQXMDLULZIOII-HAQNSBGRSA-N 0.000 description 1
- KVWJPTMNFUDCBC-XYPYZODXSA-N C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(NC=3C(=CC=C(Cl)C=3)N)N=C21 Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C(=O)NC2=C(Cl)N=C(NC=3C(=CC=C(Cl)C=3)N)N=C21 KVWJPTMNFUDCBC-XYPYZODXSA-N 0.000 description 1
- KDISMIMTGUMORD-UHFFFAOYSA-N CC(N1CCCCC1)=O Chemical compound CC(N1CCCCC1)=O KDISMIMTGUMORD-UHFFFAOYSA-N 0.000 description 1
- HHWMXZAOBMVCDA-IYARVYRRSA-N CC1=NC2=C(C=3C=CN=CC=3)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 Chemical compound CC1=NC2=C(C=3C=CN=CC=3)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 HHWMXZAOBMVCDA-IYARVYRRSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- NCUWUXHOUVYWLP-ZJUUUORDSA-N C[C@H](CC1)C(C=CCC2)=C2[C@@H]1C=O Chemical compound C[C@H](CC1)C(C=CCC2)=C2[C@@H]1C=O NCUWUXHOUVYWLP-ZJUUUORDSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- MADDWNUAYOHWRC-UHFFFAOYSA-M ClC1=CC=CC=C1[Zn]I Chemical compound ClC1=CC=CC=C1[Zn]I MADDWNUAYOHWRC-UHFFFAOYSA-M 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QRMHDGWGLNLHMN-UHFFFAOYSA-N Methyl methoxyacetate Chemical compound COCC(=O)OC QRMHDGWGLNLHMN-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 101100280403 Mus musculus F7 gene Proteins 0.000 description 1
- ZZYUWPGTXCXYMJ-UHFFFAOYSA-N N#Cc(cc1)cc2c1nc[n]2-c(nc1N(C2)CC2(F)F)nc(N2C3CCCCC3)c1NC2=O Chemical compound N#Cc(cc1)cc2c1nc[n]2-c(nc1N(C2)CC2(F)F)nc(N2C3CCCCC3)c1NC2=O ZZYUWPGTXCXYMJ-UHFFFAOYSA-N 0.000 description 1
- VOEZNNVYCXYKAV-UHFFFAOYSA-N N#Cc(cc1)cc2c1nc[n]2-c(nc1N(C2)CC2O)nc(N2C3CCOCC3)c1NC2=O Chemical compound N#Cc(cc1)cc2c1nc[n]2-c(nc1N(C2)CC2O)nc(N2C3CCOCC3)c1NC2=O VOEZNNVYCXYKAV-UHFFFAOYSA-N 0.000 description 1
- CXJRSNVYUWXTNB-UHFFFAOYSA-N NC(C(CC1)CCN1c1nc(-[n]2c(cc(cc3)Cl)c3nc2)nc(N2C3CCOCC3)c1NC2=O)=O Chemical compound NC(C(CC1)CCN1c1nc(-[n]2c(cc(cc3)Cl)c3nc2)nc(N2C3CCOCC3)c1NC2=O)=O CXJRSNVYUWXTNB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010084311 Novozyme 435 Proteins 0.000 description 1
- OCJJQVCBZZVWEY-JOCQHMNTSA-N O=C1N(C)C2=C(Cl)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C2N1[C@H]1CC[C@H](O)CC1 Chemical compound O=C1N(C)C2=C(Cl)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C2N1[C@H]1CC[C@H](O)CC1 OCJJQVCBZZVWEY-JOCQHMNTSA-N 0.000 description 1
- PJPGCYUQMNXKBP-SHTZXODSSA-N O=C1N(C)C2=C(N3CC(F)(F)C3)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C2N1[C@H]1CC[C@H](O)CC1 Chemical compound O=C1N(C)C2=C(N3CC(F)(F)C3)N=C(N3C4=CC(=CC=C4N=C3)C#N)N=C2N1[C@H]1CC[C@H](O)CC1 PJPGCYUQMNXKBP-SHTZXODSSA-N 0.000 description 1
- VUMYIHPCMZPBBC-HDJSIYSDSA-N O=C1N(C)C2=C(N3CC(F)(F)C3)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 Chemical compound O=C1N(C)C2=C(N3CC(F)(F)C3)N=C(N3C4=CC(Cl)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 VUMYIHPCMZPBBC-HDJSIYSDSA-N 0.000 description 1
- RQCBZNUBLBMIRZ-SHTZXODSSA-N O=C1N(C)C2=C(N3CCC3)N=C(N3C4=CC(F)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 Chemical compound O=C1N(C)C2=C(N3CCC3)N=C(N3C4=CC(F)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 RQCBZNUBLBMIRZ-SHTZXODSSA-N 0.000 description 1
- FSXRPOPBNKJKSY-JYJNAYRXSA-N O=C1N(C)C2=C(N3C[C@@H](F)CC3)N=C(N3C4=CC(F)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 Chemical compound O=C1N(C)C2=C(N3C[C@@H](F)CC3)N=C(N3C4=CC(F)=CC=C4N=C3)N=C2N1[C@H]1CC[C@H](O)CC1 FSXRPOPBNKJKSY-JYJNAYRXSA-N 0.000 description 1
- QUQBEMDCYNGSNO-UHFFFAOYSA-N OC(C1)CN1C1=[I]C([n]2c(cc(cc3)Cl)c3nc2)=NC(N2C3CCOCC3)=C1NC2=O Chemical compound OC(C1)CN1C1=[I]C([n]2c(cc(cc3)Cl)c3nc2)=NC(N2C3CCOCC3)=C1NC2=O QUQBEMDCYNGSNO-UHFFFAOYSA-N 0.000 description 1
- VIDHJAQYHBCOKA-XPTKOCRKSA-N OC1N([C@H]2C(C=CCC3F)=C3OCC2)c(nc(-[n]2c(cc(cc3)F)c3nc2)nc2CC3=CC=CCC3)c2N1 Chemical compound OC1N([C@H]2C(C=CCC3F)=C3OCC2)c(nc(-[n]2c(cc(cc3)F)c3nc2)nc2CC3=CC=CCC3)c2N1 VIDHJAQYHBCOKA-XPTKOCRKSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BBKCOQYMKGEAAJ-UHFFFAOYSA-M [Br-].[Zn+]C1CCC1 Chemical compound [Br-].[Zn+]C1CCC1 BBKCOQYMKGEAAJ-UHFFFAOYSA-M 0.000 description 1
- YIHLDLKWMUEDQC-HXUWFJFHSA-N [O-][NH+]1N([C@H]2c3cccc(F)c3OCC2)c(nc(-[n]2c(cc(cc3)F)c3nc2)nc2C3=CCCC=C3)c2N1 Chemical compound [O-][NH+]1N([C@H]2c3cccc(F)c3OCC2)c(nc(-[n]2c(cc(cc3)F)c3nc2)nc2C3=CCCC=C3)c2N1 YIHLDLKWMUEDQC-HXUWFJFHSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000025368 adrenal gland disease Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- VGSOYPVNPXQBSH-UHFFFAOYSA-N cyclohexyl imidazole-1-carboxylate Chemical compound C1=CN=CN1C(=O)OC1CCCCC1 VGSOYPVNPXQBSH-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CXMOEGSGXAUCNZ-UHFFFAOYSA-N ethyl 2,6-dichloro-5-nitropyrimidine-4-carboxylate Chemical compound CCOC(=O)C1=NC(Cl)=NC(Cl)=C1[N+]([O-])=O CXMOEGSGXAUCNZ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- AJQCLZMYIBWMBX-UHFFFAOYSA-N n,n-diethyl-1,3-dimethyl-1,3,2-diazaphosphinan-2-amine Chemical compound CCN(CC)P1N(C)CCCN1C AJQCLZMYIBWMBX-UHFFFAOYSA-N 0.000 description 1
- OFOMMTJRFCSXNT-UHFFFAOYSA-N n-(8-fluoro-2,3-dihydrochromen-4-ylidene)hydroxylamine Chemical compound C1=CC=C2C(=NO)CCOC2=C1F OFOMMTJRFCSXNT-UHFFFAOYSA-N 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- KWZSCXIYGVEHOB-UHFFFAOYSA-N oxan-4-amine;hydrochloride Chemical compound [Cl-].[NH3+]C1CCOCC1 KWZSCXIYGVEHOB-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- PCPUMGYALMOCHF-UHFFFAOYSA-N oxolan-3-ylmethanol Chemical compound OCC1CCOC1 PCPUMGYALMOCHF-UHFFFAOYSA-N 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001586 pre-b-lymphocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-M pyrimidine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-M 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 208000006934 radiodermatitis Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IBKSOWUYKOORFF-UHFFFAOYSA-N tert-butyl n-(2-amino-4-fluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(F)C=C1N IBKSOWUYKOORFF-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000005708 tetrahydropyranylation reaction Methods 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- HEOMKTNNZDZMJZ-UHFFFAOYSA-M zinc;benzonitrile;bromide Chemical compound Br[Zn+].N#CC1=CC=[C-]C=C1 HEOMKTNNZDZMJZ-UHFFFAOYSA-M 0.000 description 1
- HEHCQTGEYNYOSF-UHFFFAOYSA-M zinc;butanenitrile;bromide Chemical compound Br[Zn+].[CH2-]CCC#N HEHCQTGEYNYOSF-UHFFFAOYSA-M 0.000 description 1
- WRSWIWOVJBYZAW-UHFFFAOYSA-M zinc;methanidylbenzene;bromide Chemical compound Br[Zn+].[CH2-]C1=CC=CC=C1 WRSWIWOVJBYZAW-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/196,516 | 2008-08-22 | ||
| US12/196,516 US7902187B2 (en) | 2006-10-04 | 2008-08-22 | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| PCT/US2009/054663 WO2010022358A1 (en) | 2008-08-22 | 2009-08-21 | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazoio[4,5- c]pyridinyl)purine and purinone derivatives for immunosuppression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012500805A true JP2012500805A (ja) | 2012-01-12 |
| JP2012500805A5 JP2012500805A5 (https=) | 2012-09-27 |
Family
ID=41707479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011524034A Pending JP2012500805A (ja) | 2008-08-22 | 2009-08-21 | 免疫抑制のための６−置換２−（ベンズイミダゾリル）プリンおよびプリノン誘導体ならびに６−置換２−（イミダゾロ［４，５−ｃ］ピリジニル）プリンおよびプリノン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7902187B2 (https=) |
| EP (1) | EP2326647A4 (https=) |
| JP (1) | JP2012500805A (https=) |
| CA (1) | CA2735048A1 (https=) |
| WO (1) | WO2010022358A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190092573A (ko) * | 2016-12-20 | 2019-08-07 | 아스트라제네카 아베 | 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도 |
| WO2025234404A1 (ja) * | 2024-05-07 | 2025-11-13 | 全薬工業株式会社 | ピリミジン含有縮合環化合物及びその用途 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2577514T3 (es) * | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
| WO2007030438A2 (en) * | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| US20070253896A1 (en) * | 2006-02-07 | 2007-11-01 | Conforma Therapeutics Corporation | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors |
| US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| CA2646429A1 (en) * | 2006-03-09 | 2007-09-13 | Pharmacopeia, Inc. | 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
| EP2029597A4 (en) * | 2006-05-31 | 2011-11-23 | Univ California | purine analogs |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| TW200837064A (en) * | 2006-10-04 | 2008-09-16 | Pharmacopeia Inc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| TW200831104A (en) * | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7968556B2 (en) * | 2006-10-19 | 2011-06-28 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| ES2552471T3 (es) | 2007-02-07 | 2015-11-30 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
| BRPI0817503B8 (pt) * | 2007-10-05 | 2021-05-25 | Sstarbio Pte Ltd | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa |
| EA201001264A1 (ru) * | 2008-02-07 | 2011-04-29 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7 |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| KR20110117705A (ko) * | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| MY177695A (en) | 2009-10-26 | 2020-09-23 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| UA109775C2 (xx) * | 2009-10-29 | 2015-10-12 | N-вмісні гетероарильні похідні як інгібітори jak3-кінази | |
| TW201144310A (en) * | 2010-04-28 | 2011-12-16 | Daiichi Sankyo Co Ltd | [5,6] heterocyclic compound |
| NZ603155A (en) | 2010-04-30 | 2014-06-27 | Telormedix Sa | Phospholipid drug analogs |
| US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
| KR101978537B1 (ko) | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
| JP6076370B2 (ja) | 2011-12-02 | 2017-02-08 | シグナル ファーマシューティカルズ，エルエルシー | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法 |
| TWI615143B (zh) | 2012-02-24 | 2018-02-21 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EP2945636B1 (en) | 2013-01-16 | 2017-06-28 | Signal Pharmaceuticals, LLC | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| AU2014254052B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
| TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法 |
| US9782427B2 (en) | 2013-04-17 | 2017-10-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| BR112015026292B1 (pt) | 2013-04-17 | 2022-04-12 | Signal Pharmaceuticals, Llc | Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro |
| US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| EP3003313A1 (en) | 2013-05-29 | 2016-04-13 | Signal Pharmaceuticals, LLC | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| US10183949B2 (en) | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
| WO2017133657A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2017133664A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| CN117751127A (zh) * | 2021-08-20 | 2024-03-22 | 南京大美生物制药有限公司 | 一种五元含氮杂环并杂芳基类衍生物及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070021443A1 (en) * | 2005-04-05 | 2007-01-25 | Ohlmeyer Michael J | Purine and imidazopyridine derivatives for immunosuppression |
| WO2008043031A1 (en) * | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| WO2008051494A1 (en) * | 2006-10-19 | 2008-05-02 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES473201A1 (es) | 1977-09-26 | 1979-03-16 | Degussa | Procedimiento para la preparacion de 7-azabencimidazoles |
| US4813998A (en) | 1986-02-27 | 1989-03-21 | Janssen Pharmaceutica N.V. | Herbicidal 1H-imidazole-5-carboxylic acid derivatives |
| EP0277384A3 (en) | 1986-12-24 | 1990-05-23 | Janssen Pharmaceutica N.V. | 1h-imidazole-5-carboxylic acid derivatives |
| DE4007535A1 (de) | 1990-03-09 | 1991-09-12 | Hoechst Ag | Wasserunloesliche azofarbmittel, ihre herstellung und verwendung |
| JP3396924B2 (ja) | 1993-09-07 | 2003-04-14 | 日本曹達株式会社 | 活性汚泥のバルキング防止剤 |
| US5705625A (en) | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
| CN1207735A (zh) | 1995-11-27 | 1999-02-10 | 出光兴产株式会社 | 三嗪衍生物 |
| AR007115A1 (es) | 1996-05-15 | 1999-10-13 | Hoechst Ag | Cromanos sustituidos con sulfonamida, procedimiento para su preparacion, su empleo para la preparacion de medicamento o agente de diagnostico, asi como medicamento que los contiene |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| WO2000012089A1 (en) | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| WO1999024432A1 (fr) | 1997-11-12 | 1999-05-20 | Mitsubishi Chemical Corporation | Derives de purine et medicament les renfermant en tant qu'ingredient actif |
| ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| JP2002503659A (ja) | 1998-02-13 | 2002-02-05 | アベンテイス・フアルマ・ソシエテ・アノニム | 縮合した複素環式系誘導体、それらの製造及びそれらを含有する製薬学的組成物 |
| US6313129B1 (en) | 1998-08-21 | 2001-11-06 | Hughes Institute | Therapeutic compounds |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| PL354241A1 (en) | 1999-09-17 | 2003-12-29 | Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg | Kinase inhibitors as therapeutic agents |
| US6582357B2 (en) | 2000-05-24 | 2003-06-24 | Pentax Corporation | Treating instrument erecting device for use in endoscope |
| US6506738B1 (en) | 2000-09-27 | 2003-01-14 | Bristol-Myers Squibb Company | Benzimidazolone antiviral agents |
| GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| AR035230A1 (es) | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
| SE0104331D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Novel compounds |
| CA2501940A1 (en) | 2002-10-09 | 2004-04-22 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| CA2505546A1 (en) | 2002-11-08 | 2004-05-27 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells and methods of their use |
| NZ539901A (en) | 2002-11-26 | 2007-09-28 | Pfizer Prod Inc | Method of treatment of transplant rejection |
| JP2004217582A (ja) | 2003-01-16 | 2004-08-05 | Abbott Japan Co Ltd | ９ｈ−プリン誘導体 |
| KR101224300B1 (ko) | 2003-02-05 | 2013-01-21 | 바이엘 크롭사이언스 아게 | 키랄 바이사이클릭 라디칼로 ｎ-치환된 아미노 １,３,５-트라이아진, 이것의 제조방법, 이것의 조성물 및 제초제 및 식물 성장 조절제로서의 이것의 용도 |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| NZ546058A (en) | 2004-01-12 | 2010-09-30 | Ym Biosciences Australia Pty | Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| CA2596830A1 (en) | 2005-02-03 | 2006-09-14 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrimidines useful as inhibitors of protein kinase |
| CA2598076A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US20090023723A1 (en) * | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| US20070253896A1 (en) * | 2006-02-07 | 2007-11-01 | Conforma Therapeutics Corporation | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors |
| US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| CA2691214A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| TW200837064A (en) * | 2006-10-04 | 2008-09-16 | Pharmacopeia Inc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| ATE543819T1 (de) | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| US20080220256A1 (en) * | 2007-03-09 | 2008-09-11 | Ues, Inc. | Methods of coating carbon/carbon composite structures |
| TW200902025A (en) * | 2007-04-11 | 2009-01-16 | Alcon Res Ltd | Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
| CA2686485A1 (en) | 2007-05-23 | 2008-11-27 | Pharmacopeia, Llc | Purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| WO2009062059A2 (en) | 2007-11-08 | 2009-05-14 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
-
2008
- 2008-08-22 US US12/196,516 patent/US7902187B2/en active Active
-
2009
- 2009-08-21 EP EP09808894A patent/EP2326647A4/en not_active Withdrawn
- 2009-08-21 CA CA2735048A patent/CA2735048A1/en not_active Abandoned
- 2009-08-21 JP JP2011524034A patent/JP2012500805A/ja active Pending
- 2009-08-21 WO PCT/US2009/054663 patent/WO2010022358A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070021443A1 (en) * | 2005-04-05 | 2007-01-25 | Ohlmeyer Michael J | Purine and imidazopyridine derivatives for immunosuppression |
| WO2008043031A1 (en) * | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| WO2008051494A1 (en) * | 2006-10-19 | 2008-05-02 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190092573A (ko) * | 2016-12-20 | 2019-08-07 | 아스트라제네카 아베 | 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도 |
| JP2020504107A (ja) * | 2016-12-20 | 2020-02-06 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用 |
| KR102220971B1 (ko) | 2016-12-20 | 2021-02-25 | 아스트라제네카 아베 | 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도 |
| US11136340B2 (en) | 2016-12-20 | 2021-10-05 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| US11746118B2 (en) | 2016-12-20 | 2023-09-05 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| WO2025234404A1 (ja) * | 2024-05-07 | 2025-11-13 | 全薬工業株式会社 | ピリミジン含有縮合環化合物及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2326647A1 (en) | 2011-06-01 |
| WO2010022358A1 (en) | 2010-02-25 |
| WO2010022358A8 (en) | 2011-03-24 |
| US7902187B2 (en) | 2011-03-08 |
| US20090069289A1 (en) | 2009-03-12 |
| EP2326647A4 (en) | 2012-12-26 |
| CA2735048A1 (en) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7902187B2 (en) | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression | |
| US7919490B2 (en) | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression | |
| US7915268B2 (en) | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression | |
| US11958837B2 (en) | Quinazolinones as PARP14 inhibitors | |
| CA2880251C (en) | Novel heteroaryl and heterocycle compounds, composition and methods thereof | |
| EP3523305B1 (en) | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| US20080119496A1 (en) | 7-Substituted Purine Derivatives for Immunosuppression | |
| US20070021443A1 (en) | Purine and imidazopyridine derivatives for immunosuppression | |
| JP2010510211A (ja) | 免疫抑制用７−置換プリン誘導体 | |
| US20080287468A1 (en) | Purine and imidazopyridine derivatives for immunosuppression | |
| WO2009062059A2 (en) | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors | |
| WO2011075630A1 (en) | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors | |
| CN109790164B (zh) | 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物 | |
| WO2003022805A2 (en) | Heterocycle substituted purines as antiproliferative agents | |
| WO2009048474A1 (en) | 2,7,9-substituted purinone derivatives for immunosuppression | |
| EP1556379A2 (en) | Chemical compounds | |
| US20080146536A1 (en) | 2-Aminoimidazopyridines for treating neurodegenerative diseases | |
| WO2007030438A2 (en) | Aminopurine derivatives for treating neurodegenerative diseases | |
| HK40039341A (en) | Quinazolinones as parp14 inhibitors | |
| HK40039341B (en) | Quinazolinones as parp14 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120806 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120806 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140127 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140707 |